C260-1907 Screening compound: 2-[4-(1-{[(2,5-dimethylphenyl)carbamoyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)phenyl]-N-[(oxolan-2-yl)methyl]acetamide

C260-1907 Screening compound: 2-[4-(1-{[(2,5-dimethylphenyl)carbamoyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)phenyl]-N-[(oxolan-2-yl)methyl]acetamide
C260-1907 Screening compound: 2-[4-(1-{[(2,5-dimethylphenyl)carbamoyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)phenyl]-N-[(oxolan-2-yl)methyl]acetamide alternative view

Chemical Structure Depiction of ChemDiv screening compound C260-1907
2-[4-(1-{[(2,5-dimethylphenyl)carbamoyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)phenyl]-N-[(oxolan-2-yl)methyl]acetamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

C260-1907

Molecular Formula

C31H32N4O5 (C31 H32 N4 O5)

Compound Name

2-[4-(1-{[(2,5-dimethylphenyl)carbamoyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)phenyl]-N-[(oxolan-2-yl)methyl]acetamide

IUPAC name

2-[4-(1-{[(25-dimethylphenyl)carbamoyl]methyl}-24-dioxo-1234-tetrahydroquinazolin-3-yl)phenyl]-N-[(oxolan-2-yl)methyl]acetamide

SMILES

Cc1cc(NC(CN(c(cccc2)c2C(N2c3ccc(CC(NCC4OCCC4)=O)cc3)=O)C2=O)=O)c(C)cc1

InChI

InChI=1S/C31H32N4O5/c1-20-9-10-21(2)26(16-20)33-29(37)19-34-27-8-4-3-7-25(27)30(38)35(31(34)39)23-13-11-22(12-14-23)17-28(36)32-18-24-6-5-15-40-24/h3-4,7-14,16,24H,5-6,15,17-19H2,1-2H3,(H,32,36)(H,33,37)/t24-/m1/s1

InChI Key

ILWYUFDYONTFDI-XMMPIXPASA-N

MDL Number (MFCD)

MFCD14738243

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

540.62

Hydrogen Bond Acceptors Count

9.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

10.00

Number of Nitrogen and Oxygen Atoms

9

Partition Coefficient, logP

1.781

Distribution Coefficient, logD

1.781

Water Solubility, LogSw

-2.85

Polar Surface Area

85.961

Acid Dissociation Constant (pKa)

12.88

Base Dissociation Constant (pKb)

1.64

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

29.00

C260-1907 in Drug Discovery

Included in Screening Libraries

Dark Chemical Matter Library (18430 compounds)

ChemoGenomic Annotated Library for Phenotypic Screening (89798 compounds)

MCE-18 Trends in Medicinal Chemistry (51288 compounds)

Protein Tyrosine Phosphatase Non-receptor Type (PTPN) Targeted Library (32556 compounds)

Included in 1.7M Stock Database

Structure:
  • Pool
Therapeutical areas:
  • Cancer
  • Nervous system
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
  • Endocrine
Targets:
  • Phosphatases

References: we are preparing a list of scientific research reports with C260-1907 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound C260-1907?
Check Price and Availability of C260-1907, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of C260-1907 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for C260-1907
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for C260-1907
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of C260-1907 available by request